Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Brivaracetam

Brivaracetam

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Brivaracetam

22 trials tracked of Brivaracetam: 13 in phase 3 or 4 and 3 with published results. The most-cited published study has 24 citations.

22Trials tracked
13Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 13 Phase 2 6 Phase 1 3
  1. Phase 3 Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy Completed · 24 cited
  2. Phase 3 A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy Completed
  3. Phase 3 A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization Completed
  4. Phase 3 Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed
  5. Phase 3 An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Completed
  6. Phase 3 This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment Completed
Show 16 more trials
  1. Phase 3 Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures Completed
  2. Phase 3 Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy Completed
  3. Phase 3 Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures Completed
  4. Phase 3 Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy Completed
  5. Phase 3 Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy Completed
  6. Phase 3 Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV) Completed
  7. Phase 3 Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy Completed
  8. Phase 2 A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures. Completed
  9. Phase 2 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy Completed
  10. Phase 2 A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia) Completed
  11. Phase 2 Open-label, Pharmacokinetic, Safety and Efficacy Study of Adjunctive Brivaracetam in Children With Epilepsy. Completed
  12. Phase 2 A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting Completed
  13. Phase 2 Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury Completed
  14. Phase 1 A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Male Japanese Study Participants Completed
  15. Phase 1 A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil Completed
  16. Phase 1 A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese Subjects Completed

Showing the 22 most-cited and recently-updated of 22 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.